{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:36:03Z","timestamp":1789983363461,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T00:00:00Z","timestamp":1486339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"This study was self funded by the department."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec><jats:title>BACKGROUND AND OBJECTIVES<\/jats:title><jats:p>Radionuclide therapy has been used to treat patients with progressive\/metastatic paragangliomas (PGLs) and phaeochromocytomas (PCCs). The aim of the present study is to retrospectively compare the therapeutic outcomes of these modalities in patients with progressive\/metastatic PCCs and PGLs.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with progressive\/metastatic PGLs and PCCs that were subjected to radionuclide treatment in our department were retrieved from our department's database for the period 1998\u20102013. Overall survival (OS), progression free survival (PFS), event free survival (EFS), and response to treatment were calculated. Treatment toxicity was documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twenty\u2010two patients with progressive\/metastatic PGLs or PCCs were treated with either (131)I\u2010MIBG, (90)Y\u2010DOTATATE or (177)Lu\u2010DOTATATE. A total of 30 treatments were administered (16 treatments with (131)I\u2010MIBG, 2 with (177)Lu\u2010DOTATATE, and 12 with (90)Y\u2010DOTATATE. Patients treated with PRRT had increased PFS and response to treatment compared to (131)I\u2010MIBG treated patients (<jats:italic>P\u2009<\/jats:italic>&lt;\u20090.05). However, difference in OS was non significant (<jats:italic>P<\/jats:italic>\u2009=\u20090.09). There was no difference in major toxicities between groups. When comparing only patients with PGLs, OS, PFS, EFS, and response to treatment were significantly higher in the PRRT treatment group.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>PRRT treatment offers increased OS, PFS, EFS, and response to treatment compared to (131)I\u2010MIBG therapy in patients with progressive\/malignant PGLs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.24553","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T18:52:45Z","timestamp":1486407165000},"page":"425-434","source":"Crossref","is-referenced-by-count":68,"title":["Peptide Receptor Radionuclide Treatment and (131)I\u2010MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas"],"prefix":"10.1002","volume":"115","author":[{"given":"Konstantinos","family":"Nastos","sequence":"first","affiliation":[{"name":"ENETS Centre of Excellence Neuroendocrine Tumour Unit Royal Free London NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.F.","family":"Cheung","sequence":"additional","affiliation":[{"name":"ENETS Centre of Excellence Neuroendocrine Tumour Unit Royal Free London NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[{"name":"ENETS Centre of Excellence Neuroendocrine Tumour Unit Royal Free London NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Royal Free London NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Marie","family":"Quigley","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Royal Free London NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Caplin","sequence":"additional","affiliation":[{"name":"ENETS Centre of Excellence Neuroendocrine Tumour Unit Royal Free London NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Khoo","sequence":"additional","affiliation":[{"name":"ENETS Centre of Excellence Neuroendocrine Tumour Unit Royal Free London NHS Foundation Trust London UK"},{"name":"Department of Endocrinology Royal Free London NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1353.050"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1544"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31825c53fa"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2009.07.031"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0652-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00617-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2011.12.003"},{"key":"e_1_2_7_9_1","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer F","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"e_1_2_7_10_1","first-page":"101","article-title":"Peptide receptor radionuclide therapy (PRRT) for progressive, somatostatin receptor positive pheochromocytoma\/paraganglioma","volume":"49","author":"Prasad V","year":"2008","journal-title":"J Nucl Med"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3029-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1311603"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3496"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2006.03.007"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1311637"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058693"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.047738"},{"key":"e_1_2_7_18_1","first-page":"1","article-title":"Comparison of radiolabeled octreotide and meta\u2010iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma","volume":"36","author":"Tenenbaum F","year":"1995","journal-title":"J Nucl Med"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2568-7"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/110241598750004913"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03256.x"},{"key":"e_1_2_7_22_1","first-page":"660","article-title":"Potential increased tumor\u2010dose delivery with combined 131I\u2010MIBG and 90Y\u2010DOTATOC treatment in neuroendocrine tumors: a theoretic model","volume":"47","author":"Madsen MT","year":"2006","journal-title":"J Nucl Med"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2006.07.030"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.24553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.24553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T06:50:48Z","timestamp":1696488648000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.24553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,6]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/jso.24553"],"URL":"https:\/\/doi.org\/10.1002\/jso.24553","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,6]]}}}